We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+57.51%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$3.59B
AUM Growth
+$852M
Cap. Flow
-$15.9M
Cap. Flow %
-0.44%
Top 10 Hldgs %
60.96%
Holding
76
New
4
Increased
9
Reduced
2
Closed
9

Top Buys

Rank Stock Value
1
IDYA icon
IDEAYA Biosciences
IDYA
+$66.4M
2
JANX icon
Janux Therapeutics
JANX
+$33.7M
3
RVMD icon
Revolution Medicines
RVMD
+$31.9M
4
PVLA
Palvella Therapeutics
PVLA
+$11.8M
5
ALLK
Allakos
ALLK
+$11.7M

Top Sells

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$45.3M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$44M
3
IMVT icon
Immunovant
IMVT
+$39.7M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$37M
5
MRUS
Merus
MRUS
+$30.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALLK
26
DELISTED
Allakos
ALLK
$37.7M 1.05%
8,652,417
+2,592,170
+43% +$11.7M
ETNB
27
DELISTED
89bio
ETNB
$35M 0.98%
1,846,154
– –
ACRS icon
28
Aclaris Therapeutics
ACRS
$743M
$34.9M 0.97%
3,360,941
– –
CGEM icon
29
Cullinan Oncology
CGEM
$1.08B
$34.4M 0.96%
3,196,701
– –
ITOS
30
DELISTED
iTeos Therapeutics
ITOS
$24M 0.67%
1,810,835
– –
EPIX
31
DELISTED
ESSA Pharma
EPIX
$23.6M 0.66%
8,748,629
– –
OVID icon
32
Ovid Therapeutics
OVID
$442M
$22.5M 0.63%
6,851,051
– –
ACIU icon
33
AC Immune
ACIU
$241M
$22M 0.61%
7,428,379
– –
THRD
34
DELISTED
Third Harmonic Bio
THRD
$21M 0.59%
4,365,933
– –
IMA
35
ImageneBio Inc
IMA
$67.2M
$20.8M 0.58%
264,097
– –
NAMS icon
36
NewAmsterdam Pharma
NAMS
$3.33B
$18.1M 0.5%
1,521,948
– –
VIGL
37
DELISTED
Vigil Neuroscience
VIGL
$17M 0.48%
1,813,633
– –
CBIO
38
Crescent Biopharma
CBIO
$555M
$16.6M 0.46%
95,443
– –
STRO icon
39
Sutro Biopharma
STRO
$411M
$15.6M 0.43%
334,795
– –
JSPR icon
40
Jasper Therapeutics
JSPR
$20.7M
$13.6M 0.38%
990,000
– –
ANTX icon
41
AN2 Therapeutics
ANTX
$192M
$13.3M 0.37%
1,563,963
– –
VSTM icon
42
Verastem
VSTM
$536M
$12.5M 0.35%
1,685,219
+99,998
+6% +$694K
VERV
43
DELISTED
Verve Therapeutics
VERV
$12.2M 0.34%
650,000
– –
CALT
44
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$11.8M 0.33%
750,000
– –
CTMX icon
45
CytomX Therapeutics
CTMX
$714M
$11.3M 0.32%
6,595,801
– –
SLN
46
Silence Therapeutics
SLN
$549M
$8.3M 0.23%
1,508,416
– –
CDTX
47
DELISTED
Cidara Therapeutics
CDTX
$7.75M 0.22%
343,056
– –
TCRX icon
48
TScan Therapeutics
TCRX
$49.4M
$7.47M 0.21%
+2,989,474
New +$8.02M
DCTH icon
49
Delcath Systems
DCTH
$416M
$6.87M 0.19%
+1,178,787
New +$7.39M
NCEL
50
NewcelX Ltd
NCEL
$18.1M
$6.32M 0.18%
14,368
– –
1
2
3 4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2023 Portfolio in Review

As of Q2 2023, BVF Inc held 76 positions worth $3.59B, up 31% from $2.74B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

BVF Inc's Q2 2023 filing shows 4 new, 9 increased, 2 reduced and 9 closed positions. Its largest new stake was TScan Therapeutics: 2,989,474 shares worth $7.47M. The largest sale was Syndax Pharmaceuticals, an estimated $45.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • BVF Inc's largest Q2 2023 buy was TScan Therapeutics: 2,989,474 shares worth $7.47M.
  • BVF Inc added most to IDEAYA Biosciences in Q2 2023, an estimated $66.4M increase.
  • BVF Inc's biggest Q2 2023 reduction was Merus, cutting an estimated $30.1M.
  • BVF Inc fully exited Syndax Pharmaceuticals in Q2 2023, selling an estimated $45.3M.
  • BVF Inc's ten largest holdings make up 61% of its $3.59B portfolio in Q2 2023.
  • BVF Inc opened 4 new positions and closed 9 in Q2 2023.
  • BVF Inc's portfolio value rose 31% quarter-over-quarter to $3.59B.

Based on BVF Inc's 13F filing for Q2 2023, filed 14 Aug 2023.